BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

928 related articles for article (PubMed ID: 32404114)

  • 21. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of radiotherapy in multimodal treatment of pancreatic carcinoma.
    Brunner TB; Scott-Brown M
    Radiat Oncol; 2010 Jul; 5():64. PubMed ID: 20615227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant radiotherapy for locoregional Siewert type II gastroesophageal junction adenocarcinoma: A propensity scores matching analysis.
    Zhou Y; Tian M; Güngör C; Wang D
    PLoS One; 2021; 16(5):e0251555. PubMed ID: 33979405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
    Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H
    Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX.
    Lee SH; Hwang DW; Yoo C; Kim KP; Kang S; Jeong JH; Oh D; Song TJ; Lee SS; Park DH; Seo DW; Park JH; Song KB; Lee JH; Lee W; Park Y; Kwak BJ; Chang HM; Ryoo BY; Kim SC
    Cancer Res Treat; 2023 Jul; 55(3):956-968. PubMed ID: 36915253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
    Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
    J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of radiotherapy in patients with resected ampullary carcinoma: findings based on the SEER database.
    Zhao W; Wang B; Zhao A; Tian Q; Zhang L; Wang L; Zhao X; Yang J; Dong D
    HPB (Oxford); 2019 Nov; 21(11):1535-1540. PubMed ID: 31056288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma.
    Li G; Chen JZ; Chen S; Lin SZ; Pan W; Meng ZW; Cai XR; Chen YL
    Cancer Med; 2020 May; 9(10):3353-3370. PubMed ID: 32181599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
    Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
    Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
    Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
    Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN
    HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of radiation therapy sequence on survival among patients with resected pancreatic head ductal carcinoma.
    Franko J; Puri DR; Goldman CD
    Ann Surg Oncol; 2012 Jan; 19(1):26-30. PubMed ID: 21735324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative radiotherapy improves overall survival of pT4 pancreatic ductal adenocarcinoma patients after surgical resection.
    Xu Y; Zhang Y; Wu Z; Wang D; Wu W; Kuang T; Lou W
    Jpn J Clin Oncol; 2020 Jun; 50(6):679-687. PubMed ID: 32372083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Survival Effect of Radiotherapy on Stage IIB/III Pancreatic Cancer Undergone Surgery in Different Age and Tumor Site Groups: A Propensity Scores Matching Analysis Based on SEER Database.
    Wang D; Ge H; Tian M; Li C; Zhao L; Pei Q; Tan F; Li Y; Ling C; Güngör C
    Front Oncol; 2022; 12():799930. PubMed ID: 35174085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung Cancer undergoing surgery: a propensity-matched analysis.
    Wang X; Yin C; Su S; Li X; Wang C; Zhang C; Liu M
    BMC Cancer; 2018 Nov; 18(1):1067. PubMed ID: 30400782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matching study.
    Shi J; Li X; Wu Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Jun; 50(3):375-382. PubMed ID: 34402250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based on Pathologic Features.
    Moaven O; Clark CJ; Russell GB; Votanopoulos KI; Howerton R; Levine EA; Shen P
    Ann Surg; 2021 Dec; 274(6):1058-1066. PubMed ID: 31913868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis.
    Yoon MS; Lee HS; Kang CM; Lee WJ; Keum J; Sung MJ; Kim SS; Park MS; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Hwang HK; Bang S
    Gut Liver; 2022 Jan; 16(1):118-128. PubMed ID: 34140428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.